

FOR IMMEDIATE RELEASE

Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GENEGO RECEIVES 1.4 MILLION DOLLAR AWARD FROM THE MICHIGAN LIFE SCIENCE CORRIDOR

New Buffalo, Michigan, June 16, 2003 — GeneGo announced today the receipt of a 1.4 million dollar award from the Michigan Life Science Corridor (MLSC). With over 151 companies competing for 18 awards, it reinforces the life science industry's endorsement of GeneGo's technology.

"We are delighted to have received this award from MLSC," said Dr. Tatiana Nikolskaya, CEO of GeneGo. "Our MetaCore™ platform, which contains the largest human content available today, has established us as a leader in computational systems biology. MetaCore™ is the first commercially available computational platform for human Systems Biology, and is designed to assist pharmaceutical researchers in the areas of target selection, prioritization, and validation, as well as biomarker identification. We will use the funds to further develop this product and to expand our sales, customer support, and application divisions."

GeneGo will maintain its position as one of the leaders in the field by continuing to focus on new product development. Plans for the MetaCore™ platform include more advanced visualization tools, additions to the disease map library, and staying current with all relevant published literature. The company is also committed to increasing the field scientist team so that they can provide support to customers on how to apply MetaCore™ to their research programs.

In addition to the MLSC award, GeneGo has received a Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences, a division of the NIH. This grant will be used to support the development of its next product, MetaDrug™, an in silico platform for predicting metabolism and possible toxic effects of novel drug candidates. Expected to launch in the latter part of this year, MetaDrug™ will integrate advanced QSAR and expert system approaches with GeneGo's extensive database on human pathways and their software for reconstruction and visualization of metabolic and cell signaling networks. The company's growing recognition and unique technology portfolio will pave the way for additional awards from state and federal programs.

About GeneGo

GeneGo is a privately held company that develops technology and computational platforms for the pharmaceutical and life science industries in the rapidly growing field of Systems Biology. GeneGo offers the first commercially available computational platforms that integrate information about human genes, RNA, proteins, metabolites, and biological pathways to provide a deeper understanding of the molecular mechanisms of disease, and a broader yet more efficient approach to drug target selection, prioritization, and validation, as well as biomarker identification. The company's MetaCore™ and MetaDrug™ Platforms combine proprietary and public knowledge with the customer's own data to enable the researcher to model and predict the behavior of biological systems. GeneGo was founded in 2000 and is based in New Buffalo, Michigan. Additional information about GeneGo is available at www.genego.com

MetaCore is a trademark of GeneGo, Inc.